Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

INDEPENDENT LAB SERVICES

NPI: 1114329109 · YOUNGSTOWN, OH 44514 · Clinical Medical Laboratory · NPI assigned 09/22/2014

$1.71M
Total Medicaid Paid
235,009
Total Claims
80,525
Beneficiaries
31
Codes Billed
2018-01
First Month
2019-10
Last Month

Provider Details

Authorized OfficialKENDRA-TOWNSEND, NICOLE (CREDENTIALING SPECIALIST)
Parent OrganizationADO HEALTH SERVICES INC.
NPI Enumeration Date09/22/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 225,169 $1.64M
2019 9,840 $62K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80346 11,196 3,782 $142K
80361 11,464 4,031 $124K
80362 9,631 3,215 $107K
80321 9,182 2,931 $78K
80373 11,438 4,020 $78K
83992 9,091 3,242 $77K
80355 11,193 3,744 $76K
80348 11,817 4,139 $71K
80354 11,662 4,094 $70K
80353 11,630 4,091 $70K
80349 11,580 4,058 $70K
80356 11,449 4,019 $69K
80365 11,445 4,022 $69K
80324 11,261 3,826 $68K
80359 10,203 3,354 $62K
80357 8,118 2,548 $56K
80372 8,093 3,130 $55K
80366 7,807 2,713 $52K
80358 7,365 2,692 $46K
80369 6,570 2,153 $44K
80368 6,518 1,967 $44K
80345 6,520 2,037 $41K
80360 6,444 2,038 $40K
80336 5,114 1,688 $35K
80332 4,698 1,459 $32K
80338 2,729 833 $19K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 293 283 $6K
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 154 149 $3K
80305 316 240 $2K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 15 15 $321.68
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 13 12 $232.63